ArticleBMC cancer2026
Breast cancer survival rates in Sarawak, Malaysia: a central referral centre study.
Article in BMC cancer, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBreast cancer remains the most common malignancy in Malaysia, with a wide range of survival rates across regions. Sarawak, the largest state in Malaysia faces unique geographic and socioeconomic challenges, often delaying diagnosis and treatment. This study aimed to determine the survival rates and predictors of breast cancer outcomes at the state’s sole public referral centre for cancer.
methodsA retrospective study was conducted among all patients with histologically confirmed breast cancer diagnosed between 2018 and 2022 at Sarawak General Hospital. Sociodemographic, clinical and pathological data were extracted from medical records, whilst mortality was verified via the National Registration Department. Kaplan-Meier and Cox proportional hazards models were used to estimate survival rates and identify prognostic factors.
resultsA total of 1,739 patients were analysed. The mean age was 57.5 ± 12.2 years, with 46.5% presenting at advanced clinical stage III–IV. The overall 1-, 3-, and 5-year survival rates were 93.5%, 82.5%, and 74.9%, respectively. Stage at diagnosis and biomarker subtype were independent predictors of survival. Patients with stage III and IV disease had 5.0-fold and 17.8-fold higher all-cause mortality risks compared to patients with stage 1 disease (p < 0.001). ER+, PR+, HER2– tumours had the best prognosis, while triple-negative cancers showed a 2.6-fold higher risk of all-cause death (p < 0.001). Patients from indigenous ethnic communities and those living in rural settings were more likely to present with advanced disease.
conclusionBreast cancer survival in Sarawak is influenced primarily by disease stage and biomarker profile, with socioeconomic and geographic barriers contributing to delayed diagnosis. Increasing early detection, improving access to oncology care, and developing culturally tailored health literacy programs are essential to improve survival outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.